AbbVie Inc. (NYSE:ABBV) has declared another quarterly dividend of $1.73 per share. The dividend will be paid on November 16, ...
AbbVie (NYSE:ABBV) shared new real-world and pediatric safety data for VRAYLAR in MDD and bipolar I at Psych Congress 2026.
Zacks Investment Research on MSN
How AbbVie's neuroscience portfolio has transformed over the years
AbbVie ABBV has significantly transformed its neuroscience portfolio over the years, evolving it from a relatively ...
It is certainly a good Dividend King to buy in September.
With positive phase 3 results in hand, AbbVie is one step closer to expanding the reach of its key migraine preventative ...
Final results from a long-term, open-label study evaluating the safety and tolerability of VRAYLAR among pediatric patients with BP-I disorder, schizophrenia or autism spectrum disorder, which showed ...
AbbVie's dividend is a very appealing factor.
AbbVie's flagship drug is bleeding revenue quarter after quarter, yet the company just handed shareholders another raise. Find out whether the cash machine holding this payout together can survive the ...
Birdies for Brain Health is how AbbVie is raising awareness of disease states and conditions impacting brain health, ...
AbbVie launches Birdies for Brain Health with the PGA TOUR, raising funds for people affected by neurological and mental ...
AbbVie Inc. ( ABBV) on Friday announced that it presented new real-world data on VRAYLAR at Psych Congress 2026 in New Orleans, highlighting its use in adults with major depressive disorder and ...
AbbVie presented new VRAYLAR (cariprazine) data at Psych Congress 2026 in New Orleans, including results from two prospective real-world observational studies in major depressive disorder (MDD) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results